Foghorn Therapeutics Inc. (FHTX)
NASDAQ: FHTX · Real-Time Price · USD
2.010
+0.140 (7.49%)
Oct 20, 2026, 4:00 PM EDT - Market closed
Foghorn Therapeutics Revenue
Foghorn Therapeutics had revenue of $16.07M in the quarter ending June 30, 2026, with 112.68% growth. This brings the company's total for the last twelve months to $36.74M, up 51.98% year-over-year. In the year 2025, Foghorn Therapeutics had annual revenue of $30.91M with 36.75% growth. That makes Foghorn Therapeutics the 30,062nd largest company in the world by revenue and 3,988th in the United States.
Revenue (ttm)
$36.74M
Revenue Growth
+51.98%
P/S Ratio
3.25
Revenue / Employee
$346,594
Employees
106
Market Cap
119.36M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 30.91M | 8.31M | 36.75% |
| Dec 31, 2024 | 22.60M | -11.55M | -33.83% |
| Dec 31, 2023 | 34.16M | 14.93M | 77.63% |
| Dec 31, 2022 | 19.23M | 17.91M | 1,357.77% |
| Dec 31, 2021 | 1.32M | 889.00K | 206.74% |
| Dec 31, 2020 | 430.00K | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Black Diamond Therapeutics | 70.00M |
| Cue Biopharma | 37.66M |
| Armata Pharmaceuticals | 5.54M |
| NRx Pharmaceuticals | 3.39M |
| Humacyte | 2.12M |
| Spruce Biosciences | 697.00K |
| Outlook Therapeutics | -1.16M |
FHTX News
- 7 days ago - Foghorn Therapeutics downgraded to In Line from Outperform at Evercore ISI - TheFly
- 9 days ago - FHTX Investors with $100,000 in Losses Have Opportunity to Join Foghorn Therapeutics Inc. Fraud Investigation with SBS Law - Business Wire
- 18 days ago - Wedbush downgrades Foghorn on end of Lilly collaboration - TheFly
- 18 days ago - Foghorn Therapeutics downgraded to Neutral from Outperform at Wedbush - TheFly
- 18 days ago - Foghorn Therapeutics price target lowered to $5 from $12 at Guggenheim - TheFly
- 18 days ago - Foghorn Therapeutics price target lowered to $5 from $13 at H.C. Wainwright - TheFly
- 19 days ago - Foghorn Therapeutics downgraded to Hold from Buy at TD Cowen - TheFly
- 19 days ago - Foghorn Therapeutics downgraded to Neutral from Buy at BTIG - TheFly